Temozolomide Acid | TMZA | CAS#113942-30-6

MedKoo Cat#: 406753 | Name: Temozolomide Acid

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Temozolomide Acid, also known as TMZA, is a metabolite of temozolomide (TMZ) with demonstrable anticancer activity in vitro. Temozolomide, (TMZ) (brand names Temodar and Temodal and Temcad) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme.

Chemical Structure

Temozolomide Acid

CAS#113942-30-6

Theoretical Analysis

MedKoo Cat#: 406753

Name: Temozolomide Acid

CAS#: 113942-30-6

Chemical Formula: C6H5N5O3

Exact Mass: 195.0392

Molecular Weight: 195.14

Elemental Analysis: C, 36.93; H, 2.58; N, 35.89; O, 24.60

Price and Availability

Size	Price	Availability
100mg	USD 285.00	2 Weeks
250mg	USD 605.00	2 Weeks
500mg	USD 1,050.00	2 Weeks
1g	USD 1,800.00	2 Weeks
2g	USD 3,050.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Temozolomide Acid; TMZA

IUPAC/Chemical Name

3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid

InChi Key

VVTMIOYTNALQAW-UHFFFAOYSA-N

InChi Code

InChI=1S/C6H5N5O3/c1-10-6(14)11-2-7-3(5(12)13)4(11)8-9-10/h2H,1H3,(H,12,13)

SMILES Code

O=C(C1=C(N2C=N1)N=NN(C)C2=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 195.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ercelik M, Tekin C, Gurbuz M, Tuncbilekli Y, Dogan HY, Mutlu B, Eser P, Tezcan G, Parın FN, Yildirim K, Sarihan M, Akpinar G, Kasap M, Bekar A, Kocaeli H, Taskapilioglu MO, Aksoy SA, Ozpar R, Hakyemez B, Tunca B. A new nano approach to prevent tumor growth in the local treatment of glioblastoma: Temozolomide and rutin-loaded hybrid layered composite nanofiber. Asian J Pharm Sci. 2024 Dec;19(6):100971. doi: 10.1016/j.ajps.2024.100971. Epub 2024 Oct 23. PMID: 39640055; PMCID: PMC11617954. 2: Li S, Zeng F, Zhou Q, Li L, Lo H, Chen J, Fan Z, Huang G, Nie L. NIR-II Photoacoustic Imaging-Guided Chemo-Photothermal Therapy Using PA1094T Combined with Anti-CD47 Antibody: Activating Pyroptosis against Orthotopic Glioblastoma. Adv Healthc Mater. 2024 Nov 30:e2403108. doi: 10.1002/adhm.202403108. Epub ahead of print. PMID: 39614708. 3: Diaz MA, Vázquez-Gómez F, Garrido I, Arias F, Suarez J, Buño I, Lassaletta Á. Novel Fibroblast Growth Factor Receptor 3-Fatty Acid Synthase Gene Fusion in Recurrent Epithelioid Glioblastoma Linked to Aggressive Clinical Progression. Curr Oncol. 2024 Nov 18;31(11):7308-7318. doi: 10.3390/curroncol31110539. PMID: 39590169; PMCID: PMC11592913. 4: Aydın S, Ergün Y, Ghazy S, Çelebi A, Kilic T, Avşar T, Durdağı S. Synthesis of Tryptamine-Thiazolidin-4-one Derivatives and the Combined In Silico and In Vitro Evaluation of their Biological Activity and Cytotoxicity. ACS Omega. 2024 Oct 23;9(44):44262-44281. doi: 10.1021/acsomega.4c04456. PMID: 39524642; PMCID: PMC11541526. 5: Isakova AA, Druzhkova IN, Mozherov AM, Mazur DV, Antipova NV, Krasnov KS, Fadeev RS, Gasparian ME, Yagolovich AV. Glioblastoma Sensitization to Therapeutic Effects by Glutamine Deprivation Depends on Cellular Phenotype and Metabolism. Biochemistry (Mosc). 2024 Oct;89(10):1744-1758. doi: 10.1134/S0006297924100079. PMID: 39523113. 6: Jiménez R, Constantinescu A, Yazir M, Alfonso-Triguero P, Pequerul R, Parés X, Pérez-Alea M, Candiota AP, Farrés J, Lorenzo J. Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma. Int J Mol Sci. 2024 Oct 26;25(21):11512. doi: 10.3390/ijms252111512. PMID: 39519068; PMCID: PMC11546810. 7: Mishchenko TA, Klimenko MO, Guryev EL, Savelyev AG, Krysko DV, Gudkov SV, Khaydukov EV, Zvyagin AV, Vedunova MV. Enhancing glioma treatment with 3D scaffolds laden with upconversion nanoparticles and temozolomide in orthotopic mouse model. Front Chem. 2024 Oct 21;12:1445664. doi: 10.3389/fchem.2024.1445664. PMID: 39498377; PMCID: PMC11532134. 8: Haseeb M, Khan I, Kartal Z, Mahfooz S, Hatiboglu MA. Status Quo in the Liposome-Based Therapeutic Strategies Against Glioblastoma: "Targeting the Tumor and Tumor Microenvironment". Int J Mol Sci. 2024 Oct 19;25(20):11271. doi: 10.3390/ijms252011271. PMID: 39457052; PMCID: PMC11509082. 9: Datta P, Lee NS, Moolayadukkam S, Sahu RP, Yu X, Guo T, Zhou Q, Wang Y, Puri IK. In Vitro Sonodynamic Therapy Using a High Throughput 3D Glioblastoma Spheroid Model with 5-ALA and TMZ Sonosensitizers. Adv Healthc Mater. 2024 Oct 21:e2402877. doi: 10.1002/adhm.202402877. Epub ahead of print. PMID: 39434433. 10: Pak O, Kosianova A, Zaitsev S, Sharma A, Sharma H, Bryukhovetskiy I. Valproic Acid and Celecoxib Enhance the Effect of Temozolomide on Glioblastoma Cells. CNS Neurol Disord Drug Targets. 2024 Oct 18. doi: 10.2174/0118715273330268241008220702. Epub ahead of print. PMID: 39428930. 11: Chang CH, Tsai HP, Yen MH, Lin CJ. Methanolic Extract of Cimicifuga foetida Induces G1 Cell Cycle Arrest and Apoptosis and Inhibits Metastasis of Glioma Cells. Nutrients. 2024 Sep 26;16(19):3254. doi: 10.3390/nu16193254. PMID: 39408228; PMCID: PMC11478387. 12: Vatankhah A, Moghaddam SH, Afshari S, Afshari AR, Kesharwani P, Sahebkar A. Recent update on anti-tumor mechanisms of valproic acid in glioblastoma multiforme. Pathol Res Pract. 2024 Nov;263:155636. doi: 10.1016/j.prp.2024.155636. Epub 2024 Oct 3. PMID: 39395298. 13: Huang G, Ouyang M, Xiao K, Zhou H, Zhong Z, Long S, Li Z, Zhang Y, Li L, Xiang S, Ding X. AP-2α decreases TMZ resistance of recurrent GBM by downregulating MGMT expression and improving DNA damage. Life Sci. 2024 Nov 15;357:123111. doi: 10.1016/j.lfs.2024.123111. Epub 2024 Oct 4. PMID: 39369843. 14: Pourmasoumi P, Abdouss M, Farhadi M, Jameie SB, Khonakdar HA. Co-delivery of temozolomide and quercetin with folic acid-conjugated exosomes in glioblastoma treatment. Nanomedicine (Lond). 2024;19(27):2271-2287. doi: 10.1080/17435889.2024.2395234. Epub 2024 Oct 3. PMID: 39360642; PMCID: PMC11487946. 15: Şengelen A, Önay-Uçar E. Rosmarinic acid attenuates glioblastoma cells and spheroids' growth and EMT/stem-like state by PTEN/PI3K/AKT downregulation and ERK-induced apoptosis. Phytomedicine. 2024 Dec;135:156060. doi: 10.1016/j.phymed.2024.156060. Epub 2024 Sep 19. PMID: 39341126. 16: Sun T, Lin B, Sun Q, Zhang X, Wang T, Yang J, Liu X, Lu H, Lu N, Zhao K. Gambogic acid impairs the maintenance and therapeutic resistance of glioma stem cells by targeting B-cell-specific Moloney leukemia virus insert site 1. Phytomedicine. 2024 Dec;135:156070. doi: 10.1016/j.phymed.2024.156070. Epub 2024 Sep 17. PMID: 39326139. 17: Veeramachaneni RK, Suter RK, Rowland E, Jermakowicz A, Ayad NG. Glutaminase 2 as a therapeutic target in glioblastoma. Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189182. doi: 10.1016/j.bbcan.2024.189182. Epub 2024 Sep 16. PMID: 39293549. 18: Sarkar S, Kumar S, Saha G, Basu M, Ghosh MK. Glioma nanotherapy: Unleashing the synergy of dual-loaded DIM and TMZ. Int J Pharm. 2024 Nov 15;665:124697. doi: 10.1016/j.ijpharm.2024.124697. Epub 2024 Sep 11. PMID: 39270762. 19: Kim O, Sergi Z, Yu G, Yamamoto K, Quezado M, Abdullaev Z, Crooks DR, Kishimoto S, Li Q, Lu P, Blackman B, Andresson T, Wu X, Tran B, Wei JS, Zhang W, Zhang M, Song H, Khan J, Krishna MC, Brender JR, Wu J. A patient-derived cell model for malignant transformation in IDH-mutant glioma. Acta Neuropathol Commun. 2024 Sep 10;12(1):148. doi: 10.1186/s40478-024-01860-6. PMID: 39256867; PMCID: PMC11385154. 20: Peng D, Wei C, Jing B, Yu R, Zhang Z, Han L. A novel protein encoded by circCOPA inhibits the malignant phenotype of glioblastoma cells and increases their sensitivity to temozolomide by disrupting the NONO-SFPQ complex. Cell Death Dis. 2024 Aug 25;15(8):616. doi: 10.1038/s41419-024-07010-z. PMID: 39183343; PMCID: PMC11345445.